BioCryst Pharmaceuticals Inc

NASDAQ:BCRXUnited States

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Contact Information

Headquarters

4505 Emperor Blvd Ste 200DURHAM, NC, United States 27703-8457

Phone

919-859-1302

Fax

919-859-1314

Executives

Independent Chairman of the Board

Nancy Hutson

President, Chief Executive Officer, Director

Jon Stonehouse

Chief Financial Officer

Anthony Doyle

Chief Commercial Officer

Charles Gayer

Chief Research & Development Officer

Helen Thackray